Search results for "L. Bueno. Mechanisms involved in bacterial pathogen-induced intestinal mucosal barrier disruption: Therapeutic interest of mecha"

Esposito E et al. Effect of xyloglucan against Escherichia coli extraintestinal urinary tract infection: an in vivo study. Microb Physiol. Published online:  Oct 16,  2020. DOI: 10.1159/000510874
European Review for Medical and Pharmacological Sciences. 2015; 19: 1068-1076 Objective:
UEG journal. October 2016. Vol 4. Suppl. 1 Pag A651 Introduction: Gelatine tannate (GT) and xylogucan (XG) are commercially available in several countries for the oral treatment of diarrhea in children and adults. However, the mechanism of action remains poorly understood.
We are glad inform you about a recent publication to further support the usefulness of mucoprotection in the relief of symptoms and in the prevention of recurrences in uncomplicated UTIs
Acquisition allows Noventure to maintain focus on medical devices and grow therapeutic areas in which it operates Medical devices contain Olea Europaea leaf extract, showing healing properties  for ulcers and skin wounds Innovative products are CE marked and available for licensing worldwide
BioMed Research International, Volume 2013 (2013), Article ID 947072, 11 pages
Barcelona, Spain, February 22, 2018 - Noventure and Laboratorios Salvat, S.A. (Salvat), announce today that they have entered into an agreement in which Salvat will distribute Noventure’s nasal mucoprotection product in Spain and Portugal. The product contains a mucomimetic agent that forms a protective barrier over the nasal epithelial mucosa.
Presented at GFHGHP 2012. Presented as oral communication at the 33rd edition of the Congress from the Groupe Francophone d'Hépato-Gastroentérologie et Nutrition Pédiatriques, Nantes (France),March 2012.  Abstract: New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 2: antibacterial activity.